Management of skin metastases of ovarian cancer: a novel therapeutic approach
Anne‐Marie Lüchtenborg, Jörg Sahlmann, Kristin Technau‐Hafsi, Natalia Volegova-Neher et autres
0 citationsStrahlentherapie und Onkologie
Beate Rautenberg
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
86Publications signalées
2021Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
PARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentBRCA gene mutations in cancerAdvanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Publications récentes
Is re-irradiation combined with chemotherapy an option for inoperable local recurrence of previously irradiated breast cancer? A collection of cases
Raluca Stoian, I Juhasz-Böss, Beate Rautenberg, Henning Schäfer et autres
0 citationsStrahlentherapie und Onkologie
Real‐world progression‐free survival and overall survival in patients with HR + / HER2 − advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study
P. Fasching, Cosima Veronika Maria Brucker, Thomas Decker, Anne Engel et autres
0 citationsInternational Journal of Cancer
Treatment with Mirvetuximab-Soravtansin—first clinical experience in advanced ovarian cancer in a comprehensive cancer center
I. Schwörer, Sarah Huwer, Beate Rautenberg, Jakob Neubauer et autres
0 citationsFrontiers in Oncology
Abstract PS5-04-27: Quality of life in patients with advanced breast cancer (aBC) treated with ribociclib (RIB) in the real-world RIBANNA trial
P. A. Fasching, C. Brucker, T Decker, Anne Engel et autres
0 citationsClinical Cancer Research
Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Raphaël Leman, Etienne Müller, Angélina Legros, Nicolas Goardon et autres
0 citations
Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Raphaël Leman, Etienne Müller, Angélina Legros, Nicolas Goardon et autres
0 citations
Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Raphaël Leman, Etienne Müller, Angélina Legros, Nicolas Goardon et autres
0 citations
Supplementary Figure S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Raphaël Leman, Etienne Müller, Angélina Legros, Nicolas Goardon et autres
0 citations
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Raphaël Leman, Etienne Müller, Angélina Legros, Nicolas Goardon et autres
0 citations
Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Raphaël Leman, Etienne Müller, Angélina Legros, Nicolas Goardon et autres
0 citations
Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Raphaël Leman, Etienne Müller, Angélina Legros, Nicolas Goardon et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.